Cancer (MAVERICK) Holmes Mcguire Veteran Affairs Medical Center NCT01292291 PROMIS - Prostate MRI Men at risk of PCa who University 714 NR Not yet April 2013 III-3, Imaging Study - have been advised to College London diagnostic recruiting Population 1 Evaluation of have a prostate biopsy Hospitals case-control UK Magnetic study Resonance Imaging in the Diagnosis and Characterization of Prostate Cancer NCT01858688 A Phase II, Prospective Men with histologically Dana-Farber 130 2 years Recruiting July 2018 III-3, Study of MRI in the confirmed PCa with all of Cancer Institute diagnostic Population 1 Reclassification of Men the following features: case-control USA Considering Active Min. 10 core prostate study Surveillance in Prostate biopsy showing Cancer histologically-confirmed PCa within 12 months of enrolment; Gleason ≤3+3; No Gleason grade ≥4; ≤3 total cores positive; ≤50% of any given core involved with cancer; No evidence on biopsy of extracapsular extension; PSA within one month of enrolment: <10 ng/mL; Clinical stage: ≤T2a & N0 or NX & M0 Prostate Magnetic Men with clinical suspicion Turku University February III-3, NCT02388126 150 3 months Recruiting Resonance Imaging in of PCa and/or previous Hospital 2016 diagnostic Population Patient With Previous negative prostate biopsies case-control 1/Other Negative Biopsies study Finland (PROMANEG)
Cancer (MAVERICK) Holmes Mcguire Veteran Affairs Medical Center NCT01292291 Population 1 UK PROMIS - Prostate MRI Imaging Study - Evaluation of Magnetic Resonance Imaging in the Diagnosis and Characterization of Prostate Cancer Men at risk of PCa who have been advised to have a prostate biopsy University College London Hospitals 714 NR Not yet recruiting April 2013 III-3, diagnostic case-control study NCT01858688 Population 1 USA A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer Men with histologically confirmed PCa with all of the following features: Min. 10 core prostate biopsy showing histologically-confirmed PCa within 12 months of enrolment; Gleason ≤3+3; No Gleason grade ≥4; ≤3 total cores positive; ≤50% of any given core involved with cancer; No evidence on biopsy of extracapsular extension; PSA within one month of enrolment: <10 ng/mL; Clinical stage: ≤T2a & N0 or NX & M0 Dana-Farber Cancer Institute 130 2 years Recruiting July 2018 III-3, diagnostic case-control study NCT02388126 Population 1/Other Finland Prostate Magnetic Resonance Imaging in Patient With Previous Negative Biopsies (PROMANEG) Men with clinical suspicion of PCa and/or previous negative prostate biopsies Turku University Hospital 150 3 months Recruiting February 2016 III-3, diagnostic case-control study
1397_Final_MSAC_Assessment_Report.docx